MEDIA

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

July 3, 2019

Grifols selected to build its first intravenous solutions manufacturing line in Africa

June 27, 2019

Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2018

Show more news

Media contacts

Journalist or media professional?

Our Media Relations team is available at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.

Not a journalist?

For general questions and requests, please contact corporatecomms@grifols.com.

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

MEDIA

Grifols announces FDA approval of Xembify®, 20% subcutaneous immunoglobulin for primary immunodeficiencies

Grifols selected to build its first intravenous solutions manufacturing line in Africa

Grifols discloses transfers of value made to European healthcare professionals and health-sector organizations in 2018

Media contacts

Grifols announces FDA approval of Xembify^®, 20% subcutaneous immunoglobulin for primary immunodeficiencies